| IV-04 Vanessa Baier PBPK model-guided assessment of a liver function test Thursday 15:00-16:30 |
| IV-05 Pavel Balazki PB-QSP model of type 2 diabetes for individualized prediction of treatment combination outcomes with metformin, DPP4i, and SGLT2i. Thursday 15:00-16:30 |
| IV-06 Sara Bettonte Cabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling Thursday 15:00-16:30 |
| IV-10 Letizia Carrara Prospective predictions of drug pharmacokinetics and food effect in pediatrics via PBPK modelling Thursday 15:00-16:30 |
| IV-13 Marylore Chenel Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children Thursday 15:00-16:30 |
| IV-17 Yumi Cleary Physiologically-based pharmacokinetic modelling of basmisanil to evaluate CYP3A mediated victim and perpetrator drug-drug interaction propensity Thursday 15:00-16:30 |
| IV-27 Laura Fuhr Peeling the grapefruit – investigating the drug interaction potential of grapefruit juice as CYP3A4 inhibitor using physiologically-based pharmacokinetic modeling Thursday 15:00-16:30 |
| IV-39 Helena Loer Dose Adaptations for Drug-Gene and Drug-Drug Interactions involving Clopidogrel – A Physiologically based Pharmacokinetic (PBPK) Modeling Approach Thursday 15:00-16:30 |
| IV-42 Fatima Zahra Marok Physiologically-based pharmacokinetic modeling of drug-drug interactions with ketoconazole and its metabolite deacetyl-ketoconazole Thursday 15:00-16:30 |
| IV-44 Nina Nauwelaerts Physiologically-Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to Sildenafil and Bosentan: a contribution from the ConcePTION Project Thursday 15:00-16:30 |
| IV-46 Fiona Plait Physiologically Based Pharmacokinetic Modeling of a CYP3A4-Mediated Drug-Drug Interaction: Prediction of Victim of Induction, not Inhibition, with a Moderate Fraction Metabolized by CYP3A4 Thursday 15:00-16:30 |
| IV-47 Alicja Puszkiel A minimal PBPK model for plasma and cerebrospinal fluid pharmacokinetics of trastuzumab in patients with leptomeningeal carcinomatosis Thursday 15:00-16:30 |
| IV-48 Javier Reig-López A Physiologically Based Pharmacokinetic Model for Open Acid and Lactone Forms of Atorvastatin and Its Two Metabolites Thursday 15:00-16:30 |
| IV-51 Ayatallah Saleh Elucidating the complex pharmacokinetics of voriconazole leveraging a middle-out approach Thursday 15:00-16:30 |
| IV-52 Morwarid Shahhossini Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock Thursday 15:00-16:30 |
| IV-53 Yesong Shin Population pharmacokinetic modelling for enterohepatic circulation of leflunomide in healthy Korean Thursday 15:00-16:30 |
| IV-55 Erik Sjögren A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework Thursday 15:00-16:30 |
| IV-61 Eunsol Yang Prediction of gastric pH-mediated drug exposure changes using physiologically based pharmacokinetic modeling: A case study of itraconazole Thursday 15:00-16:30 |
